Sr Director, US Medical Early Assets - Market Access

AstraZeneca•Wilmington, DE

12d•Hybrid

About The Position

The Sr Director, US Medical Early Assets - Market Access is the strategic lead for shaping US access and value strategy for BBU portfolio pipeline assets from late discovery through Phase 2. The role ensures that payer, health-system, policy, pricing, and affordability considerations are incorporated early into asset development, evidence generation, and investment decisions. As the senior US access voice on cross-functional asset teams, the Senior Director provides clear, evidence-based recommendations to strengthen future differentiation, reimbursement, and patient access. The role influences across a complex global matrix and represents US access in global and US asset teams and governance forums. It works with functions including Clinical Development, Medical, HEOR, Regulatory, Commercial, Finance, Policy, and global market access organizations. The position is based at AstraZeneca’s Wilmington, Delaware campus headquarters for its US Biopharma business. Employees work in person an average of at least three days per week, with flexibility around individual circumstances.

Requirements

Bachelor’s degree in health economics, public health, pharmacy, life sciences, business, economics, or a related discipline.
Eight or more years of progressive experience in the pharmaceutical, biotechnology, healthcare, payer, or consulting environment, including substantial experience in US Market Access, HEOR, pricing and reimbursement, or early asset strategy.
Deep understanding of the US payer and health-system environment, including commercial and government payers, medical and pharmacy benefit dynamics, pricing and reimbursement, utilization management, distribution, site-of-care considerations, and relevant policy trends.
Strong understanding of HEOR, real-world evidence, payer research, economic modeling, and value proposition development, with the ability to translate technical analyses into strategic recommendations.
Demonstrated experience representing a function or market perspective on cross-functional asset teams, governance forums, or senior decision-making bodies.
Ability to influence senior stakeholders and lead across Clinical Development, Medical, HEOR, Regulatory, Commercial, Finance, Policy, and global market access organizations without direct authority.
Strong strategic judgment and ability to make clear recommendations amid scientific, commercial, and access uncertainty.
Excellent communication skills, including synthesizing complex information, constructing a compelling value narrative, and influencing senior and global stakeholders.
Ability to manage multiple assets, priorities, and decision timelines in a complex, matrixed environment.

Nice To Haves

An advanced degree such as an MPH, MS, PharmD, PhD, or MBA is strongly preferred; preferred fields include health economics, outcomes research, public health, pharmacy, medicine, science, economics, or business.
Experience spanning more than one relevant discipline, such as Market Access, HEOR, Clinical Development, Medical Affairs, new product planning, pricing, policy, or finance.
Direct experience supporting early-stage or first-in-class assets from late discovery through Phase 2.
Experience influencing global asset strategy and translating US access needs into global development and evidence plans.
Experience contributing to governance decisions involving asset progression, indication prioritization, evidence investment, licensing, or portfolio prioritization.
Experience developing innovative pricing, contracting, or value-based access approaches.
Therapeutic-area experience relevant to the assigned pipeline portfolio.
Experience coaching colleagues or building organizational capability in early market access, HEOR, payer strategy, or value development.

Responsibilities

Define US payer-relevant elements of the Target Product Profile, including clinical endpoints, comparators, subpopulations, and line of therapy, and shape differentiation claims relevant to payers and health systems.
Provide US access input to clinical and real-world evidence plans, including endpoints, patient-reported outcomes, inclusion and exclusion criteria, study duration, head-to-head studies, and external controls.
Lead early value story development, outline core claims, and define requirements for future AMCP dossier modules and global value dossiers.
Develop US WAC and NET ranges, reference pricing considerations, budget impact boundaries, and contracting scenarios, documenting assumptions and risks.
Co-create early economic models and real-world evidence plans addressing burden of illness, treatment patterns, comparative effectiveness, adherence, and persistence.
Assess the policy landscape, including Medicare, Medicaid, ACA, IRA/Part D redesign, 340B, and state policies, as well as site-of-care and channel dynamics and their implications for development and launch.
Plan and synthesize early payer and IDN advisory input and rapid tests, such as concept reviews, value message testing, and coverage criteria simulations.
Maintain competitive and class access analyses covering coverage criteria, step and edit rules, utilization management, and coding and reimbursement precedents; identify opportunities to differentiate and anticipate barriers.
Build access assumptions for early forecasts, including gross-to-net, access mix, utilization-management intensity, and speed to coverage, and partner with Finance on rNPV and scenario analyses for governance.
Represent US access in global and US asset teams and at governance gates, including indication sequencing, go/no-go decisions, and TPP approval, and provide clear, evidence-backed recommendations.
Operate within US promotional and pre-approval communication standards and company policies, and ensure research and external interactions meet compliance requirements.